International ClinicsMedical News
International Clinics Newsroom · · 1 min read
Daily

Botulinum toxin type E: phase 3 results show effect within 8 hours and a short duration

  • The Aesthetic Surgery Journal published phase 3 results for trenibotulinumtoxinE in frown lines.
  • At day 7, 60.0% responded to trenibotulinumtoxinE versus 0.6% on placebo.
  • With trenibotulinumtoxinE, improvement began at 8 hours, peaked at day 7 and lines returned by day 21.
  • Most side effects of trenibotulinumtoxinE were mild, and the product is still investigational.
A doctor injects botulinum toxin into a woman's forehead
A doctor injects botulinum toxin into a woman's forehead Photo: AI-generated image (Gemini)
Published:

Familiar Botox-type products use botulinum toxin type A, whereas trenibotulinumtoxinE (trenibotE) uses serotype E. The Aesthetic Surgery Journal published results of its pivotal phase 3 trial for glabellar (frown) lines on 25 October 2026.

Study design

The double-blind, placebo-controlled trial enrolled adults with moderate-to-severe frown lines, including people who had and had not received toxin before. Participants were randomised 3:1 to 700 units of trenibotE or placebo. The success bar was strict: lines rated none or mild with at least a two-grade improvement, judged by both investigator and participant. The trial also tracked participants whose appearance affected them psychologically.

Also read: Meta-analysis of 65 trials: Botox improves patients' satisfaction with their appearance versus placebo

Results

  • At day 7, 60.0% responded on trenibotE versus 0.6% on placebo.
  • Improvement began at hour 8, peaked at day 7, and lines returned to moderate-to-severe by day 21.
  • Treatment satisfaction at day 7 was 77.6% vs 5.1%, and satisfaction with natural-looking results 78.5% vs 9.0%.
  • Most adverse events were mild and nonserious.

Why it matters

A fast-acting, short-lasting option may suit people who hesitate to try toxin for the first time because they worry about a long-lasting result. Allergan Aesthetics describes trenibotE as investigational, meaning it is not yet approved.

Sources: Aesthetic Surgery Journal via PubMed, Allergan Aesthetics via PR Newswire

This story is relayed from the source named above; responsibility for its content rests with the original source.

FAQ

What is trenibotulinumtoxinE?

TrenibotulinumtoxinE (trenibotE) is a botulinum toxin serotype E being developed to treat frown lines between the eyebrows.

What were the phase 3 results for trenibotulinumtoxinE?

At day 7, 60.0% of participants responded to trenibotulinumtoxinE versus 0.6% on placebo.

How fast does trenibotulinumtoxinE work and how long does it last?

TrenibotulinumtoxinE began working at about 8 hours, peaked at day 7, and frown lines returned by day 21.

Was trenibotulinumtoxinE safe in the phase 3 trial?

Most adverse events with trenibotulinumtoxinE in the phase 3 trial were mild, nonserious and unrelated to treatment.

Is trenibotulinumtoxinE available?

No. Allergan Aesthetics describes trenibotulinumtoxinE as an investigational product.

How would you rate this story?
3,004
Latest news
A fluoride-free gel that may rebuild tooth enamel, from the University of Nottingham Jackson 5's Marlon Jackson reveals he has lived with prostate cancer for four years Tip of the day: get your flu vaccine early, before winter peaks Every plant-based food in a UK study contained fungal toxins, all within EU guideline levels Tip of the day: spit, don't rinse, after brushing your teeth Energy drinks appear 11 times more often in cardiac arrest reports, preliminary study finds ISAPS global survey: eyelid surgery leads, breast lift grows fastest and filler declines Hippocrates: "Life is short, and Art long" Born on this day: William Beaumont and the hole in a stomach that rewrote digestion Tip of the day: sleep at least 7 hours a night, on a regular schedule
The latest-news bar is closed. You can bring it back any time with the “Latest news” button in the menu.